Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, Single-Center Clinical Trial.

IF 4 3区医学 Q1 ANDROLOGY World Journal of Mens Health Pub Date : 2024-10-01 Epub Date: 2024-01-02 DOI:10.5534/wjmh.230164

Marco-Jose Rivero, Rohit Reddy, Akhil Muthigi, Raghuram Reddy, Sunwoo Han, Isildinha M Reis, Mehul Patel, Ranjith Ramasamy

{"title":"Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, Single-Center Clinical Trial.","authors":"Marco-Jose Rivero, Rohit Reddy, Akhil Muthigi, Raghuram Reddy, Sunwoo Han, Isildinha M Reis, Mehul Patel, Ranjith Ramasamy","doi":"10.5534/wjmh.230164","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate patient satisfaction and symptom control in hypogonadal men transitioning from other testosterone therapies to oral testosterone undecanoate (TU).Materials and methods: In this open-label clinical trial, men aged 18 to 75 years with hypogonadism were switched to oral TU after a sufficient washout of previous testosterone therapies. Treatment satisfaction and symptom control were primarily measured using the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) and quantitative androgen deficiency in aging males (qADAM) questionnaires, respectively. Secondary outcomes included changes in serum testosterone (T), estradiol (E2), hematocrit (HCT), and prostate-specific antigen (PSA) levels.Results: Forty-one men participated, with significant improvements in all TSQM-9 scores observed over 6 months. Symptom control as measured by qADAM remained consistent. There was a significant increase in serum T and E2 levels, but HCT and PSA levels remained stable.Conclusions: Switching to oral TU from other testosterone therapies is associated with increased patient satisfaction and stable hypogonadal symptom control.","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":"762-771"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439809/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Mens Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5534/wjmh.230164","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ANDROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate patient satisfaction and symptom control in hypogonadal men transitioning from other testosterone therapies to oral testosterone undecanoate (TU).

Materials and methods: In this open-label clinical trial, men aged 18 to 75 years with hypogonadism were switched to oral TU after a sufficient washout of previous testosterone therapies. Treatment satisfaction and symptom control were primarily measured using the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) and quantitative androgen deficiency in aging males (qADAM) questionnaires, respectively. Secondary outcomes included changes in serum testosterone (T), estradiol (E2), hematocrit (HCT), and prostate-specific antigen (PSA) levels.

Results: Forty-one men participated, with significant improvements in all TSQM-9 scores observed over 6 months. Symptom control as measured by qADAM remained consistent. There was a significant increase in serum T and E2 levels, but HCT and PSA levels remained stable.

Conclusions: Switching to oral TU from other testosterone therapies is associated with increased patient satisfaction and stable hypogonadal symptom control.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

曾接受过睾酮治疗的男性口服十一酸睾酮的患者满意度：一项开放标签、单中心临床试验。

目的：评估从其他睾酮疗法过渡到口服十一酸睾酮（TU）的性腺功能减退男性患者的满意度和症状控制情况：在这项开放标签临床试验中，年龄在 18 岁至 75 岁之间的性腺功能减退症男性患者在对之前的睾酮疗法进行充分清洗后改用口服 TU。治疗满意度和症状控制情况主要分别使用 9 项药物治疗满意度问卷（TSQM-9）和老年男性雄激素缺乏定量问卷（qADAM）进行测量。次要结果包括血清睾酮（T）、雌二醇（E2）、血细胞比容（HCT）和前列腺特异性抗原（PSA）水平的变化：41 名男性参加了治疗，在 6 个月的时间里，他们的 TSQM-9 各项评分均有明显改善。用 qADAM 测量的症状控制情况保持一致。血清 T 和 E2 水平明显增加，但 HCT 和 PSA 水平保持稳定：结论：从其他睾酮疗法转为口服 TU 与患者满意度提高和性腺功能减退症状控制稳定有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊